Table 3.
Plasma lipids and biochemical measurements at baseline and after 12 weeks of intervention (Medians and 25th–75th percentiles)
| High ALA-DAG (n 10) | High ALA-TAG (n 13) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | End of study | Baseline | End of study | ||||||||
| Median | 25th–75th percentiles | Median | 25th–75th percentiles | P* | Median | 25th–75th percentiles | Median | 25th–75th percentiles | P† | P‡ | |
| Total cholesterol (mmol/l) | 5·9 | 5·2–6·2 | 5·6 | 4·9–6·0 | 0·1 | 5·4 | 5·1–5·8 | 5·4 | 5·0–6·1 | 0·6 | 0·2 |
| LDL-cholesterol (mmol/l) | 4·0 | 3·1–4·3 | 3·7 | 3·0–4·2 | 0·1 | 3·3 | 3·1–3·8 | 3·6 | 3·1–4·3 | 0·2 | 0·06 |
| HDL-cholesterol (mmol/l) | 1·3 | 1·2–1·4 | 1·3 | 1·1–1·50 | 0·8 | 1·1 | 1·1–1·4 | 1·2 | 1·0–1·4 | 0·2 | 0·5 |
| TAG (mmol/l) | 1·3 | 1·0–1·7 | 1·2 | 1·0–1·5 | 0·4 | 1·5 | 1·3–2·0 | 1·6 | 1·4–2·1 | 0·6 | 0·3 |
| NEFA (μmol/l) | 0·53 | 0·44–0·60 | 0·40 | 0·33–0·54 | 0·1 | 0·43 | 0·34–0·58 | 0·53 | 0·40–0·63 | 0·3 | 0·02 |
| ApoA-1 (g/l) | 1·4 | 1·3–1·5 | 1·4 | 1·3–1·5 | 0·5 | 1·4 | 1·3–1·6 | 1·4 | 1·3–1·5 | 0·6 | 0·7 |
| ApoB (g/l) | 1·0 | 0·7–1·1 | 0·9 | 0·8–1·0 | 0·4 | 0·9 | 0·8–1·0 | 0·9 | 0·9–1·0 | 0·1 | 0·1 |
| Glucose (mmol/l) | 5·5 | 5·0–5·9 | 5·5 | 5·2–5·8 | 0·7 | 5·8 | 5·4–6·2 | 5·5 | 5·3–6·0 | 0·8 | 0·7 |
| Insulin (pmol/l) | 61·5 | 45·0–81·3 | 63·0 | 50·5–79·8 | 0·6 | 80·0 | 63·0–109·0 | 83·0 | 48·0–116·5 | 0·9 | 1·0 |
| HbA1c (%) | 5·6 | 5·3–5·9 | 5·7 | 5·5–5·9 | 0·02 | 5·5 | 5·3–6·0 | 5·7 | 5·4–5·9 | 0·6 | 0·1 |
| C-peptide (pmol/l) | 900 | 735–1097 | 883 | 805–1063 | 0·6 | 994 | 792–1270 | 1021 | 802–1278 | 0·8 | 1·0 |
| HOMAir§ | 2·2 | 1·6–3·0 | 2·3 | 1·6–2·8 | 0·6 | 3·0 | 2·2–3·8 | 3·0 | 1·9–4·4 | 0·8 | 0·9 |
| hsCRP (mg/l) | 1·9 | 1·3–3·1 | 1·6 | 1·1–1·9 | 0·2 | 1·5 | 0·7–2·8 | 1·5 | 0·7–2·6 | 0·5 | 0·1 |
| TSH (mU/l) | 1·0 | 0·9–2·5 | 1·3 | 0·8–1·8 | 0·8 | 1·6 | 1·1–1·9 | 1·6 | 1·3–2·0 | 0·3 | 0·4 |
ALA, α-linolenic acid; DAG, diacylglycerol; HOMAir, homeostasis model assessment for insulin resistance; hsCRP, high-sensitivity C-reactive protein; TSH, thyroid-stimulating hormone.
* Within the high-ALA-DAG group (prior to Bonferroni correction).
† Within the high-ALA-TAG group (prior to Bonferroni correction).
‡ Comparing change from baseline to the end of the study between the high-ALA-DAG and high-ALA-TAG groups (prior to Bonferroni correction).
§ HOMAir = (fasting plasma insulin (mU/l) × fasting plasma glucose (mmol/l))/22·5, where 1 mU/l = 6·945 pmol/l.